NATALIE PEARSON: Open Payments
NPI 1740673862 · CENTRAL CITY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$419 in 23 payments from 13 companies in 2025. Trend: 2023 $198 · 2024 $155 · 2025 $419
Food & beverage: $419
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $49 |
| E.R. Squibb & Sons, L.L.C. | 3 | $46 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Novo Nordisk Inc | 2 | $31 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Ardelyx, Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
Products named: CAPLYTA, UZEDY, REXULTI, ELIQUIS, IBSRELA, YUPELRI, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across NE — which companies pay providers there.
